In humans, hepatic CYP46A1, A4GNT, PCLO, HSF2BP, KCNJ16, and MFSD2A were also found to be elevated in MASH patients compared with healthy controls (Figure 2A, right panel). This evidence concerns the gene MFSD2A and metabolic dysfunction-associated steatohepatitis.